Market: NASD |
Currency: USD
Address: 27 West 24th Street
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Show more
📈 Tourmaline Bio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$56.20
-
Upside/Downside from Analyst Target:
143.71%
-
Broker Call:
22
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-13
-
EPS Estimate:
-0.97
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$15.118000 |
- |
2023-10-20 |
- |
Dividend payout |
| $0.100000 |
- |
2023-10-20 |
- |
Stock split |
|
Total Amount for 2023: $15.218000 |
📅 Earnings & EPS History for Tourmaline Bio, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-08-13 | -0.9 |
| 2025-05-02 | -0.89 |
| 2025-03-13 | -0.86 |
| 2024-11-07 | -0.78 |
| 2024-08-08 | -0.68 |
| 2024-05-13 | -0.55 |
| 2024-03-19 | -0.81 |
| 2023-11-14 | -1.77 |
📰 Related News & Research
No related articles found for "tourmaline bio".
